Vanguard Capital Wealth Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.3K Hold
13,000
0.02% 130
2026
Q1
$50.4K Hold
13,000
0.05% 116
2025
Q4
$25.4K Sell
13,000
-500
-4% -$820 0.02% 126
2025
Q3
$11.4K Sell
13,500
-2,500
-16% -$1.84K 0.01% 133
2025
Q2
$11.6K Hold
16,000
0.01% 114
2025
Q1
$13.8K Sell
16,000
-15,500
-49% -$23K 0.02% 111
2024
Q4
$52.9K Sell
31,500
-3,500
-10% -$8.37K 0.06% 110
2024
Q3
$99.8K Hold
35,000
0.1% 107
2024
Q2
$81.9K Sell
35,000
-1,500
-4% -$3.92K 0.06% 132
2024
Q1
$107K Sell
36,500
-3,500
-9% -$9.93K 0.08% 140
2023
Q4
$120K Sell
40,000
-6,000
-13% -$17.2K 0.1% 131
2023
Q3
$145K Sell
46,000
-13,000
-22% -$42.3K 0.13% 116
2023
Q2
$228K Sell
59,000
-16,500
-22% -$47.5K 0.21% 104
2023
Q1
$209K Buy
75,500
+52,500
+228% +$110K 0.21% 104
2022
Q4
$41.4K Buy
23,000
+500
+2% +$965 0.05% 117
2022
Q3
$48K Sell
22,500
-1,700
-7% -$4.28K 0.06% 108
2022
Q2
$65K Sell
24,200
-2,500
-9% -$9.3K 0.07% 121
2022
Q1
$115K Sell
26,700
-18,800
-41% -$77.2K 0.08% 144
2021
Q4
$235K Buy
+45,500
New +$244K 0.17% 116

Other funds holding NAUT

Vanguard Capital Wealth Advisors's NAUT Position: Q2 2026 in Review

Vanguard Capital Wealth Advisors held its Nautilus Biotechnolgy (NAUT) position steady in Q2 2026 at 13,000 shares worth $24.3K. The position accounts for 0.02% of the portfolio, ranked #130.

Vanguard Capital Wealth Advisors first reported a position in NAUT in Q4 2021 and has held it in 19 quarters since. The position peaked at $235K in Q4 2021. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Vanguard Capital Wealth Advisors held 13,000 shares of Nautilus Biotechnolgy worth $24.3K as of Q2 2026.
  • Vanguard Capital Wealth Advisors left its Nautilus Biotechnolgy share count unchanged in Q2 2026.
  • Nautilus Biotechnolgy made up 0.02% of Vanguard Capital Wealth Advisors's portfolio in Q2 2026, its #130 holding.
  • Vanguard Capital Wealth Advisors first reported a position in Nautilus Biotechnolgy in Q4 2021 and has held it in 19 quarters since.
  • Vanguard Capital Wealth Advisors's Nautilus Biotechnolgy position peaked at $235K in Q4 2021.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.